中文产业新闻· 医学界·· 10 hours agoPickScore82
Novartis Remibrutinib Wins FDA Approval for Symptomatic Dermographism in Adults Inadequately Controlled by H1 Antihistamines
In brief
The FDA approved Novartis' BTK inhibitor remibrutinib on October 7 for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. This is the drug's second approved indication in the United States.
Why it matters
The article lists complete response rates at weeks 12 and 24 in the RemIND study with p values, letting readers compare efficacy against antihistamine up-dosing and omalizumab.
Source: 中文产业新闻 · weixin.sogou.com